Valye reports for unlimited access

Cytosorbents Corp is a medical technology company specializing in blood purification devices that use biocompatible, highly porous polymer beads to remove harmful substances from blood and other bodily fluids. Its products include CytoSorb, ECOS-300CY, VetResQ, and the PuriFi pump. CytoSorb is approved in the European Union and distributed in over 70 countries to treat critical illnesses characterized by severe inflammation, such as sepsis, COVID-19, trauma, and liver failure. The company is actively pursuing regulatory approvals in the U.S. and Canada for DrugSorb-ATR, a device designed to reduce perioperative bleeding in patients on antithrombotic drugs undergoing cardiac surgery. Cytosorbents has established multiple global distribution and co-marketing agreements with companies such as Fresenius Medical Care AG, Aferetica s.r.l., Terumo Cardiovascular Group, and B. Braun Avitum AG. The company’s business model relies on regulatory approvals, clinical validation, market acceptance, and partnerships to commercialize its products.

PMGC Holdings Inc. operates as a diversified holding company with four wholly owned subsidiaries: Northstrive Biosciences (biopharmaceuticals focusing on engineered probiotics for obesity-related muscle preservation), PMGC Capital LLC (multi-strategy investment firm), Pacific Sun Packaging, Inc. (specialty packaging for sensitive IT hardware components), and AGA Precision Systems LLC (precision CNC machining for aerospace, defense, and industrial sectors). The company divested its skincare business in early 2025 to focus on larger markets and biotechnology assets. Its subsidiaries serve diverse customers including OEMs, contract manufacturers, data center operators, and defense contractors. The company pursues growth through acquisitions and strategic investments, with recent deals expanding its manufacturing footprint and product offerings.

Vor Biopharma Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases, with telitacicept as a key product candidate. The company has actively raised capital through public and private offerings to fund clinical trials and pre-commercialization efforts. It maintains strong liquidity with over $450 million in cash, equivalents, and short-term investments as of the end of 2025. The company operates under governance structures that include cybersecurity risk oversight by the Board's Audit Committee and management. Vor Biopharma is not currently involved in any material legal proceedings.

Franklin Crypto Trust is a Delaware statutory trust formed in 2024 that offers the Franklin Crypto Index ETF (ticker EZPZ). The Fund passively tracks the CF Institutional Digital Asset Index, which includes a basket of major digital assets weighted by free float market capitalization. The Fund commenced operations on February 20, 2025, and issues shares only to Authorized Participants in Creation Units of 50,000 shares. Shares are listed and traded on the Cboe BZX Exchange. The Fund's digital assets are custodied by Coinbase Custody, with Coinbase Inc. as Prime Broker, and cash is held by The Bank of New York Mellon. The Sponsor is Franklin Holdings, LLC, and Franklin Distributors, LLC acts as the marketing agent. The Fund's NAV is calculated daily based on CF Reference Rates aggregating spot prices from multiple exchanges. The Fund is a passive, non-leveraged vehicle that does not use derivatives. The Sponsor assumes ordinary fees and expenses up to specified limits, while the Fund bears transaction costs related to digital asset trading. The Fund's shares provide investors access to digital assets through traditional brokerage accounts without the need to manage wallets or keys directly.

Kelso Technologies Inc., incorporated in 1987 and headquartered in British Columbia, Canada, is a product engineering company specializing in the research, development, production, and distribution of proprietary equipment for transportation applications. The company primarily manufactures specialized tank car equipment, including safety relief valves, vacuum relief valves, bottom outlet valves, and angle valves, which are critical for the safe handling and transport of hazardous and non-hazardous commodities. Kelso operates through two wholly owned subsidiaries, Kelso Technologies (USA) Inc. and KIQ X Industries Inc., with manufacturing and R&D facilities in Bonham, Texas, and West Kelowna, British Columbia. The company has developed an automated suspension-based Advanced Driver-Assistance System (ADAS) for wilderness terrain vehicles, targeting emergency and commercial applications in challenging environments. Kelso's products emphasize operational safety, economic advantages, and environmental protection. The company maintains a domestic US supply chain to mitigate tariff risks and holds certifications from the Association of American Railroads. Financially, Kelso reported revenues of approximately $10.78 million and net income of $447,397 for fiscal 2025, with a strong liquidity position and no long-term debt. The company is focused on obtaining regulatory approvals for new products and managing costs amid industry cyclicality and macroeconomic pressures.

EUBG is a holding company incorporated in Nevada that conducts its business through subsidiaries in Hong Kong and China. Its primary operating subsidiary in China provides digital marketing consulting and related services aimed at start-up and small-size companies, helping them leverage e-commerce platforms and build brand presence. The company’s services include marketing consultation, digital commerce empowerment, and agency-based sourcing and marketing, often integrated with the Chuangyetianxia APP platform developed by a related party. EUBG’s business model relies on performance-based and fixed-fee arrangements with clients, with a significant portion of revenue generated through the APP platform. The company recently expanded into the fintech sector by acquiring a Hong Kong money lender entity. EUBG faces operational challenges including customer concentration, regulatory compliance in China, and restrictions on cash transfers within its corporate structure.

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates primarily targeting oncology and immunology indications. In February 2026, the company expanded its pipeline by acquiring dual-targeting CAR-T assets, including TPST-2003, an autologous CD19/BCMA CAR-T therapy in clinical development for relapsed or refractory multiple myeloma. The CAR-T portfolio also includes other autologous, allogeneic, and in vivo dual-targeting therapies targeting hematologic malignancies, solid tumors, and immunology diseases such as lupus. The small molecule pipeline features amezalpat, a selective PPARα antagonist for first-line hepatocellular carcinoma, which is Phase 3-ready with regulatory designations, and TPST-1495, a dual EP2/EP4 antagonist planned for Phase 2 study in familial adenomatous polyposis funded by the National Cancer Institute. The company emphasizes a capital-efficient development strategy leveraging partner support and external funding to advance multiple programs while managing internal cash resources. Manufacturing is outsourced to third parties with internal oversight. The company faces competition from large pharmaceutical and biotech firms developing similar therapies but differentiates through its dual-targeting CAR-T architecture and first-in-class small molecules.

Electro-Sensors, Inc. is a Nasdaq-listed company (ticker: ELSE) with recent SEC filings providing financial data through the fiscal year ended December 31, 2025. The company reported positive net income and earnings per share, alongside strong liquidity ratios indicating a solid short-term financial position. Publicly available information includes shareholder meeting outcomes and appointment of auditors. News coverage over recent years has focused on the company's improving returns on capital and valuation considerations, though detailed descriptions of its business model, industry, and product offerings are not disclosed in the available SEC excerpts.

Steele Bancorp Inc is a bank holding company headquartered in Mifflinburg, Pennsylvania, formed by the merger of Mifflinburg Bancorp and Northumberland Bancorp effective August 1, 2025. The company owns Central Penn Bank & Trust, a state-chartered commercial bank with thirteen branches serving four Pennsylvania counties. The bank offers deposit accounts, consumer and commercial loans, residential real estate loans, trust services, and brokerage services through third parties. The company focuses on community banking with local decision-making and personalized service. As of December 31, 2025, Steele Bancorp had $1.26 billion in assets, $918 million in loans, and $1.11 billion in deposits. The company employs 177 people and operates under a single reportable segment. It is regulated by federal and state banking authorities and complies with capital adequacy and other regulatory requirements.

TechCom, Inc. is a shell company with no current operations. Historically, it acquired a Chinese broadband technology company, Beijing Innotrek Technology Co. Ltd, which specialized in network communications and broadband installation services, but this subsidiary is no longer active. The company has undergone several corporate changes including re-domiciling to Delaware and a name change. As of the latest filings, TechCom has no revenue, no research and development expenses, and no intellectual property. The company is seeking a merger target to establish operations but currently faces significant financial and operational challenges.

Gold Fields Limited operates as a global gold mining company with significant operations in Australia, South Africa, Ghana, Peru, and Chile. The company’s financial statements are prepared in U.S. dollars under IFRS standards. It reports various non-IFRS financial measures such as all-in sustaining costs and adjusted free cash flow to provide additional insight into operational efficiency and financial health. The company maintains liquidity with substantial cash reserves and current assets exceeding current liabilities as of the end of 2024. Gold Fields has access to credit facilities and has managed bridge and syndicated loans to support acquisitions and refinancing activities. The company also discloses environmental and regulatory matters and sustainability metrics including greenhouse gas emissions.

Lingerie Fighting Championships, Inc. (LFC) is a sports entertainment company that produces and promotes live events and televised programming featuring predominantly female athletes engaging in wrestling and MMA fighting techniques for mature audiences. The company operates a reality series and sells branded merchandise such as apparel and DVDs. LFC has developed a substantial social media presence and has hosted numerous live events in the U.S. and Europe. The business model centers on event promotion, content production, and brand licensing, with distribution through digital, broadcast, and pay-per-view channels. LFC competes with larger sports entertainment entities like WWE and UFC, as well as other media entertainment providers. The company faces regulatory considerations related to event licensing and content distribution but is currently not regulated as a full contact sport [S1].

QHSLab, Inc. operates a digital health platform designed to assist independent primary care practices in identifying and managing behavioral health conditions and allergic diseases. The platform integrates into existing clinical workflows, enabling digital health assessments, risk stratification, automated documentation, and ongoing patient engagement outside traditional office visits. The company’s revenue model is based on recurring subscription and service fees charged to medical practices on a per-patient, per-month basis. The AllergiEnd® product line complements the platform by providing FDA-cleared allergy diagnostic devices and treatment services, allowing primary care providers to manage allergic diseases in-office. Target customers are typically small, independent physician-led practices that bill Medicare and commercial insurance. The company employs a focused sales strategy emphasizing capital efficiency and short sales cycles. QHSLab competes in a fragmented and competitive market with various digital health and allergy diagnostic providers. The company reported revenues of $2.7 million in 2025 with improving gross margins and a net income influenced by debt extinguishment gains. Liquidity metrics as of December 31, 2025, show a current ratio of 1.96 and cash ratio of 1.41. The company’s growth strategy includes expanding adoption among primary care practices and developing additional clinical domains and partnerships, subject to capital and regulatory factors.

BioScience Health Innovations, Inc., formerly known as Nowtransit Inc., rebranded to reflect its strategic focus on advanced health science innovations and proprietary delivery systems. The company operates primarily through its subsidiary Best 365 Labs, which markets a portfolio of clinically-tested, natural health and wellness products targeting bacterial, viral, mental health, and metabolic challenges. Key products include Be On-Guard sprays, brain support supplements, and patent-pending Methylene Blue formulations. The company emphasizes mitochondrial health as a preventive medicine approach and is developing the MODS Max digital platform to enhance direct-to-consumer sales and subscription services. Efforts to expand include upgrading e-commerce infrastructure, pursuing international registrations, and engaging pharmacy and clinical partners for broader distribution. Financially, the company has shown revenue growth and profitability in recent periods, with ongoing capital needs and market liquidity challenges due to its OTC Pink Market listing and penny stock status [S1][S2].

American Exceptionalism Acquisition Corp. A is a special purpose acquisition company formed to raise capital through an IPO to pursue a business combination with one or more target companies. Incorporated in the Cayman Islands, it completed its IPO in September 2025, issuing Class A ordinary shares and private placement shares to its sponsor. The proceeds from the IPO are held in a trust account pending the identification and completion of a business combination within a specified timeframe. The company has no operating history or revenue as of the latest filings and reports a net loss primarily related to operating expenses and costs associated with the IPO and formation activities.

Kenon Holdings Ltd. is a publicly traded holding company listed on the NYSE and TASE under the ticker KEN. The company operates mainly through two reportable segments: OPC Power Plants in Israel and CPV Group in the United States. OPC Power Plants focuses on generation and supply of electricity and energy in Israel, including development, construction, and operation of power plants. CPV Group operates renewable and conventional energy power plants in the United States. Kenon's business model centers on energy generation with a mix of renewable and natural gas assets. The company manages liquidity through operating cash flows, equity offerings, and debt financing, with a focus on compliance with financial covenants and maintaining sufficient liquidity to meet obligations. As of December 31, 2025, Kenon reported consolidated revenue of approximately $871.9 million USD and net income of $148.3 million USD, supported by strong liquidity metrics. The company has ongoing capital expenditures for project development and maintenance, including the Basin Ranch project in the U.S. Recent developments include OPC Energy enhancing its stake in power plants and securing additional funding.

AudioCodes Ltd. is an Israeli company specializing in voice communications technology for enterprises, contact centers, and service providers. Its offerings include voice networking infrastructure, cloud-based platforms, and Voice AI applications designed to support unified communications and contact center environments. The company’s solutions are structured across three layers: hardware devices and infrastructure, cloud platforms for provisioning and management, and AI applications for contact center and compliance functionalities. AudioCodes has a global presence, serving customers in over 100 countries through direct sales and a broad network of channel partners. The company has evolved from traditional VoIP hardware to include cloud-based managed services and AI-driven voice productivity tools. Its Live Platform enables cloud-based voice connectivity and AI services integration with major UCaaS providers such as Microsoft Teams, Webex, and Zoom. AudioCodes continues to invest in AI capabilities, expanding its portfolio with products like Meeting Insights, Interaction Insights, and Voca CIC, which leverage conversational AI and large language models to enhance customer engagement and operational efficiency. The company reported fiscal year 2025 revenue of $245.6 million and net income of $8.96 million, with solid liquidity metrics. It faces competitive pressures from established telecommunications equipment providers and is subject to macroeconomic and geopolitical risks impacting supply chains and technology adoption.

Allurion Technologies, Inc. is an emerging growth company known for its Allurion Gastric Balloon System, which received FDA PMA approval in early 2026. The company operates in the medical product sector, focusing on weight management solutions. Despite regulatory progress, the company faces significant financial challenges, including a substantial net loss and liquidity constraints as reflected in its low current and cash ratios. The company’s common stock was delisted from the NYSE in March 2026 due to non-compliance with market capitalization requirements and is currently trading on the OTCID Market while appealing the delisting decision. Capital structure adjustments have been made through warrant inducement transactions to improve financial flexibility.

MeiraGTx Holdings plc operates as a vertically integrated genetic medicines company focused on developing and commercializing gene therapy products. The company has developed a proprietary riboswitch gene regulation platform enabling precise control of gene expression via oral small molecules. It owns two GMP-compliant viral vector manufacturing facilities in London and Shannon, supporting clinical and commercial supply. MeiraGTx's pipeline includes late-stage clinical programs for radiation-induced xerostomia, Parkinson's disease, and inherited retinal dystrophies, among others. Strategic collaborations with Johnson & Johnson, Hologen Limited, and Eli Lilly support research, development, manufacturing, and commercialization efforts. The company also acquired Smart Immune's assets to expand into cell therapy. Financially, MeiraGTx reported $81.4 million in revenues and a net loss of $114.2 million for 2025, with liquidity ratios indicating moderate short-term financial flexibility.

Ondas Holdings Inc operates in the communication equipment industry, providing wireless and unmanned aerial systems (UAS) data solutions primarily to critical infrastructure, defense, public safety, and government sectors. The company develops technology compliant with evolving wireless broadband standards and aims to expand its market presence through organic growth and acquisitions. Ondas has a concentrated customer base and relies significantly on government contracts, which are subject to budgetary and regulatory uncertainties. The company maintains strong liquidity with substantial cash reserves and current assets exceeding current liabilities by a wide margin as of the end of 2025.

Scienture Holdings, Inc. is a specialty pharmaceutical company operating through its wholly owned subsidiary Scienture LLC, which focuses on the commercialization and development of products for cardiovascular and central nervous system diseases. Scienture LLC launched its first commercial product, Arbli™ (SCN-102), an FDA-approved oral liquid formulation of losartan potassium for hypertension and related indications, in the third quarter of 2025. The company also acquired REZENOPY™, a naloxone nasal spray product, and holds exclusive U.S. commercialization rights. The product portfolio includes FDA-approved and pipeline candidates targeting CNS and CVS conditions, with ongoing clinical development and regulatory activities. Scienture LLC's strategy includes advancing product candidates through clinical studies, driving growth via dedicated sales and marketing, pursuing strategic business development opportunities, and expanding its development pipeline through internal R&D and partnerships [S1].

Pulsenmore Ltd. develops and markets innovative, non-invasive portable ultrasound devices designed for home use, enabling patients to perform self-scans with telehealth support. Its primary products include the Pulsenmore ES for prenatal care, the Pulsenmore FC for follicular monitoring in IVF and fertility preservation, and the Pulsenmore MC in early development for pulmonary fluid monitoring. The company’s products are approved in multiple international markets and leverage proprietary ultrasound technology integrated with smartphone applications to facilitate remote monitoring and consultation. Pulsenmore’s business model includes direct sales to healthcare providers and partnerships with major Israeli health organizations, with a growing focus on expanding commercial presence in the United States following FDA clearance. The company maintains a robust intellectual property portfolio and a manufacturing process compliant with international quality standards. Pulsenmore’s strategy emphasizes expanding geographic reach, enhancing product offerings, and developing recurring revenue streams through software services.

ECARX Holdings Inc. develops and supplies automotive computing platforms and software solutions globally. Its product portfolio includes infotainment head units, digital cockpits, autonomous driving control units, and vehicle chipsets. The company serves a diversified customer base including Geely Holding and other automotive OEMs and Tier 1 suppliers. ECARX’s revenue streams comprise sales of goods, software licensing, and services such as design and development and connectivity. The company maintains a significant R&D focus with approximately 70% of its 1,400+ employees engaged in research and development across multiple global locations. ECARX has expanded its in-house production capabilities and made strategic acquisitions to support growth. It has established partnerships with Qualcomm and Samsung to advance automotive intelligence technologies and software-defined vehicles. The company faces competitive industry dynamics and regulatory requirements in China related to foreign investment and intelligent connected vehicle testing.

HCM IV Acquisition Corp. is a Cayman Islands exempted blank check company (SPAC) formed in September 2025 to effect a business combination with one or more target companies. The company completed its IPO in February 2026, raising gross proceeds of $287.5 million, which are held in a trust account invested in low-risk securities. The company has not commenced operations or generated revenues as of the latest filing and has not identified any business combination target. The Sponsor holds founder shares and private placement warrants and has agreed to waive certain redemption rights. The company faces competition from other SPACs and investment entities in identifying suitable targets. The management team has experience in acquisitions and growth investing but there is no assurance of completing a business combination. The company is an emerging growth company with limited operating history and financial data.

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel drug candidates, primarily brilaroxazine, targeting schizophrenia and potentially other neuropsychiatric disorders. The company has completed Phase 2 and Phase 3 clinical trials for brilaroxazine, including the RECOVER and REFRESH studies, with positive safety and efficacy data reported. Reviva is advancing regulatory interactions with the FDA, including a recommended second Phase 3 trial for schizophrenia. The company has recently raised capital through a $10 million public offering and implemented a reverse stock split to address Nasdaq listing requirements. Financially, Reviva reported a net loss for fiscal year 2025 and maintains liquidity sufficient to fund operations into early 2027. The company faces risks related to Nasdaq compliance, regulatory approval timelines, and the need for additional capital to support ongoing and planned clinical trials.

HCM III ACQUISITION CORP. is a Cayman Islands exempted blank check company incorporated in April 2025. It was formed to effect a merger, share exchange, or similar business combination with one or more target companies. The company completed its IPO in August 2025, issuing 25.3 million units and raising $253 million, which was placed in a trust account invested in U.S. government securities. The Sponsor holds founder shares and has agreed to certain obligations to protect trust account funds. The company had not commenced operations as of December 31, 2025, and generates no operating revenues until after completing its initial business combination. The company completed a business combination with Murano PV, S.A. DE C.V., a Mexican development company, as announced in March 2024. The management team has experience in acquiring assets at disciplined valuations and aims to complete a business combination with an established business of scale. The company is subject to Nasdaq rules requiring the business combination to have a fair market value of at least 80% of trust assets and to acquire controlling interest in the target. Public shareholders have redemption rights upon completion of the business combination. The company is an emerging growth company and a smaller reporting company, eligible for certain reduced disclosure obligations.

Gores Holdings X, Inc. / CI is a special purpose acquisition company (SPAC) that completed its IPO in May 2025, raising approximately $358.8 million. The company’s business model is to identify and complete an initial business combination with one or more target businesses. It currently holds funds in a trust account and has no operating revenues or history. The company’s sponsor and management have significant influence over the business combination process, including voting rights. Liquidity as of the end of 2025 is limited, with current liabilities exceeding current assets. The company is subject to various risks inherent to blank check companies, including potential conflicts of interest and limited shareholder control over the initial business combination.

21Shares Solana ETF is a Delaware statutory trust formed in 2024 that issues shares representing fractional interests in a portfolio primarily composed of SOL tokens, the native digital asset of the Solana blockchain. The Trust is a passive investment vehicle that seeks to track the performance of SOL as measured by a specified pricing benchmark, adjusted for expenses and liabilities. The Trust may stake a portion of its SOL holdings to earn rewards, which are distributed to shareholders after fees. Shares are created and redeemed in large blocks (Creation Baskets) through authorized participants, with transactions facilitated by a Prime Broker and multiple SOL Custodians. The Trust is not registered as an investment company under the Investment Company Act and is not regulated as a commodity pool. The Sponsor, a subsidiary of 21co Holdings Limited and ultimately FalconX Holdings Limited, manages the Trust's marketing, registration, and fee arrangements but does not exercise day-to-day control over custodians or trustees. The Trust calculates NAV daily based on the Pricing Benchmark and follows fair value accounting standards for SOL. The Trust reported a net loss of approximately $4.15 million for the fiscal year ended December 31, 2025.

Enlight Renewable Energy Ltd. is a renewable energy platform founded in 2008 and publicly listed on Nasdaq since 2023 and on the Tel Aviv Stock Exchange since 2010. The company develops, finances, constructs, owns, and operates utility-scale renewable energy projects, primarily solar and wind, across multiple geographies including Israel, Europe, the United States, and the MENA region. Revenue is mainly generated from electricity sales under long-term power purchase agreements (PPAs) with terms ranging from 5 to 30 years, supplemented by some merchant sales and revenues from green certificates and services. Enlight controls the full project life cycle, enabling strategic capital allocation and operational management. The company has demonstrated growth through new project additions and geographic expansion, including recent investments in energy storage projects in Europe and the U.S. Financing is sourced through project finance debt, equity offerings, and tax equity partnerships. The company faces operational and geopolitical risks, including the ongoing conflict in Israel and regulatory requirements in the U.S.

Electra Battery Materials Corp is a Canadian company specializing in the refining and recycling of battery materials, primarily cobalt, nickel, lithium, manganese, and graphite, for the electric vehicle market. The company operates a hydrometallurgical refinery in Ontario, Canada, and holds mineral properties in the Idaho Cobalt Belt, including the Iron Creek Project. Electra's business model centers on producing battery-grade materials from both mining feedstock and recycled battery scrap (black mass) using proprietary hydrometallurgical processes. The company has established long-term supply contracts with Glencore and offtake agreements with Stratton Metals and LGES. Electra is in the advanced stages of constructing and commissioning its refinery, with a US$73 million budget approved in early 2026 and plans for commercial production in late 2027. The company has received government funding commitments and is actively managing capital needs through private placements and debt restructuring. Electra is publicly listed on the TSX Venture Exchange and Nasdaq under the ticker ELBM.

REED'S, INC. is a branded beverage company specializing in natural, premium, and functional beverages under the Reed's and Virgil's brands. Its products, numbering around 50, are distributed through a network of seven independent manufacturers and five distribution centers, reaching over 32,000 outlets in the U.S. and Asia-Pacific. The company emphasizes real ginger, clean-label ingredients, and functional formulations, competing in the U.S. carbonated soft drink market. It operates an asset-light model relying on co-packers and distributors to scale production efficiently and manage costs. The product portfolio includes craft ginger beers, real ginger ales, handcrafted sodas, functional sodas with adaptogens, and ready-to-drink alcoholic beverages. Distribution channels span natural and specialty wholesale distributors, direct-store-delivery, warehouse delivery, and wholesale distribution. Key customers include major natural food retailers, grocery chains, club stores, liquor stores, and convenience outlets. The company has expanded its international presence with subsidiaries in Asia-Pacific. It faces competition from large beverage companies and regional producers in both non-alcoholic and RTD alcoholic beverage segments. The company reported a net loss of $15.842 million for fiscal 2025 and maintains liquidity with a current ratio of 1.6. It carries a Senior Secured Loan due in September 2026, secured by most assets, with refinancing risks noted. Recent news reports indicate a 20% sales drop and Q2 losses in 2025, highlighting operational and market challenges.

Armata Pharmaceuticals, Inc. focuses on developing high-purity, pathogen-specific bacteriophage therapeutics as alternatives to traditional antibiotics for treating antibiotic-resistant and difficult-to-treat bacterial infections. The company’s proprietary technology enables targeting of specific bacteria while preserving the human microbiome. Armata has completed three Phase 2 clinical trials, including studies of inhaled AP-PA02 for chronic pulmonary infections caused by Pseudomonas aeruginosa in cystic fibrosis and non-cystic fibrosis bronchiectasis patients, and intravenous AP-SA02 for complicated Staphylococcus aureus bacteremia. The company has enhanced manufacturing processes to produce high-titer, high-purity phage products with lot-to-lot consistency, supporting potential commercialization. Armata operates manufacturing and R&D facilities in California and Australia. The company’s stock trades on the NYSE American under the ticker ARMP.

Planet 13 Holdings Inc. operates as a vertically integrated cannabis cultivator, producer, distributor, and retailer across Nevada, California, Illinois, and Florida. The company holds multiple cultivation, production, distribution, and dispensary licenses in these states. Its flagship retail location is the Planet 13 Las Vegas Superstore, a large dispensary with entertainment features. The company also operates several other dispensaries and manufacturing facilities, offering products under several proprietary brands. Planet 13 maintains a significant customer loyalty database and engages in wholesale and retail cannabis sales. The company’s operations are subject to extensive regulatory compliance and industry-specific risks.

EDAP TMS SA develops and markets minimally invasive medical devices using robotic energy-based ultrasound technology. Its core product, the Focal One® HIFU system, is designed for focal therapy of prostate cancer and has potential applications in other urological and gynecological conditions. The company combines imaging, robotics, and precise energy delivery to offer non-invasive treatment options. EDAP has a growing global install base, including a significant presence in the U.S. market, supported by clinical evidence and reimbursement frameworks. The company’s financials show revenue growth in its core HIFU segment alongside ongoing net losses reflecting investment in growth and innovation.

Equillium, Inc. is a clinical-stage biotechnology company incorporated in 2017, engaged in the research and development of novel biopharmaceutical product candidates, primarily EQ504 and EQ302. The company has not yet achieved regulatory approval for any product and has no commercial revenues. Its operations include clinical and preclinical development, in-licensing of product rights, and business development activities. Equillium relies on third-party manufacturers and CROs for production and clinical studies. The company completed a private placement in 2025 to raise capital for advancing clinical trials, particularly a Phase 1 study for EQ504. Equillium faces significant risks including ongoing operating losses, the need for substantial additional funding, regulatory uncertainties, and the challenge of establishing commercialization capabilities. The company also navigates risks related to international trade policies and geopolitical factors affecting its supply chain.

Dyadic International Inc operates in the biotechnology sector with a focus on microbial protein production platforms and related technologies. The company has been advancing its alternative proteins business and vaccine development efforts, including securing grants for antibody development. In 2025, Dyadic announced a strategic shift towards the ancillary protein market and underwent leadership changes. The company reported significant revenue growth in Q2 2025 and has been narrowing its losses. Dyadic maintains liquidity with cash, short-term investments, and a current ratio above 2. The company has faced Nasdaq listing compliance challenges related to minimum bid price and market value of listed securities but has regained compliance and is actively monitoring its status. Capital raising efforts include an at-the-market equity offering program.